| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_60da379fb33c192ef77f86a60c5ac029 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D411-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D327-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-12 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-52
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-506
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-513
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P31-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D407-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D405-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D411-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D473-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D307-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D327-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-10
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07H19-06 |
| filingDate |
2004-03-05-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate |
2008-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3081ceb058f2a9a4ebd13ba412fbbdc8
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_bc007c78e22beb7ecd04f0e570e332e7
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4ffa889343eff0120a28da7b031d8eab |
| publicationDate |
2008-12-23-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
US-7468436-B2 |
| titleOfInvention |
Method of resolution and antiviral activity of 1,3-oxathiolane nucleoside enantiomers |
| abstract |
A process for the resolution of a racemic mixture of nucleoside enantiomers that includes the step of exposing the racemic mixture to an enzyme that preferentially catalyzes a reaction in one of the enantiomers. The nucleoside enantiomer (−)-2-hydroxymethyl-5-(5-fluorocytosin-1-yl)-1,3-oxathiolane is an effective antiviral agent against HIV, HBV, and other viruses replicating in a similar manner. |
| priorityDate |
1990-02-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |